INVESTOR ALERT: Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. Announced by Glancy Prongay & Murray LLP

LOS ANGELES--(BUSINESS WIRE)--

Glancy Prongay & Murray LLP announces that a class action lawsuit has been filed on behalf of a class (the "Class") of investors who purchased securities of Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") AMPE between January 13, 2014 and August 21, 2014, inclusive (the "Class Period") concerning the Company's and its officers' possible violations of federal securities laws. Investors have until July 7, 2015 to file a motion for appointment as a lead plaintiff.

The complaint alleges that the Company and its executives violated federal securities laws by failing to disclose that: (1) the clinical research organization conducting the STEP Study lacked autonomy; and (2) the trial drug supply for the STEP Study was shipped to clinical sites at lower temperatures than were permitted by the drug's specifications; and, as a result of the Company's fraudulent conduct investors have been severely damaged. On August 21, 2014, the Company announced that, "due to temperature deviations below product specifications during shipments to the Ampion™ STEP Study clinical sites, release of data will be delayed." On this news the Company's shares declined sharply, thereby damaging investors. Then on April 20, 2015, Ampio announced that, "the multiple injection STRIDE study AP008 did not reach its primary endpoint against the saline control test." On this news, shares of Ampio fell $5.18 per share, to close at $2.69, or more than 65.8%, on April 24, 2015.

If you purchased shares of Ampio, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150701006229/en/